ORSIGHT PHARMA LTD

The technology is an injectable product for intravitreal delivery in neovascular AMD that is based on a new active compound which introduces novel mechanism of action. The market of wet AMD is dominated with drugs that target VEGFR/VEGF axis of actio

Small molecule treatment designed to preserve vision and prevent blindness through a novel VEGF-independent mechanism.

People suffering from Neovascular Age-Related Macular Degeneration